Scarica l'app Stockscreener
53.96
2.77%
-1.54
Pre-mercato:
54.33
0.37
+0.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HIMS Giù?
Forum
Previsione
Precedente Chiudi:
$55.50
Aprire:
$54.99
Volume 24 ore:
27.95M
Relative Volume:
0.81
Capitalizzazione di mercato:
$11.74B
Reddito:
$1.78B
Utile/perdita netta:
$164.40M
Rapporto P/E:
78.20
EPS:
0.69
Flusso di cassa netto:
$236.51M
1 W Prestazione:
+8.70%
1M Prestazione:
+17.25%
6M Prestazione:
+62.82%
1 anno Prestazione:
+225.65%
Intervallo 1D:
$53.91
$56.52
Intervallo di 1 settimana:
$47.48
$56.52
Portata 52W:
$15.73
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Nome
Hims Hers Health Inc
Settore
Industria
Telefono
415-851-0195
Indirizzo
2269 CHESTNUT ST, SAN FRANCISCO
Confronta HIMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
53.96 | 12.54B | 1.78B | 164.40M | 236.51M | 0.69 |
|
PG
Procter Gamble Co
|
156.83 | 369.56B | 84.28B | 16.07B | 14.05B | 6.51 |
|
UL
Unilever Plc Adr
|
62.32 | 154.20B | 64.99B | 6.71B | 6.53B | 2.4495 |
|
CL
Colgate Palmolive Co
|
82.13 | 67.31B | 20.00B | 3.05B | 3.37B | 3.56 |
|
KMB
Kimberly Clark Corp
|
125.47 | 42.46B | 18.88B | 2.38B | 2.10B | 7.26 |
|
KVUE
Kenvue Inc
|
18.25 | 36.44B | 15.14B | 1.42B | 1.63B | 0.74 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-23 | Downgrade | Needham | Buy → Hold |
| 2025-06-04 | Reiterato | Needham | Buy |
| 2025-04-29 | Downgrade | TD Cowen | Buy → Hold |
| 2025-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Downgrade | Citigroup | Neutral → Sell |
| 2025-01-07 | Iniziato | BTIG Research | Buy |
| 2024-12-17 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-08-22 | Iniziato | Needham | Buy |
| 2024-08-09 | Downgrade | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-04-16 | Downgrade | Jefferies | Buy → Hold |
| 2024-04-10 | Iniziato | Canaccord Genuity | Buy |
| 2024-02-28 | Aggiornamento | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2023-12-07 | Iniziato | Imperial Capital | In-line |
| 2023-07-28 | Iniziato | TD Cowen | Outperform |
| 2023-04-11 | Iniziato | Robert W. Baird | Neutral |
| 2023-02-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-08 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-07-15 | Iniziato | SVB Leerink | Underperform |
| 2022-04-14 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | Deutsche Bank | Hold |
| 2021-12-02 | Iniziato | Jefferies | Hold |
| 2021-11-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Iniziato | BofA Securities | Neutral |
| 2021-05-20 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Iniziato | Truist | Hold |
| 2021-03-09 | Iniziato | Credit Suisse | Neutral |
| 2021-03-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-02-17 | Iniziato | Citigroup | Neutral |
| 2021-02-12 | Iniziato | Piper Sandler | Neutral |
| 2021-02-08 | Iniziato | Tigress Financial | Buy |
Mostra tutto
Hims Hers Health Inc Borsa (HIMS) Ultime notizie
Hims & Hers Health (HIMS): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Best Healthcare Stocks To Watch NowSeptember 15th - MarketBeat
Promising Healthcare Stocks To Keep An Eye OnSeptember 14th - MarketBeat
Hims & Hers Stock: How It Found Itself in the FDA’s Crosshairs - Barron's
Hims & Hers falls after FDA commissioner says its Super Bowl ad breached regulations - Sherwood News
Hims & Hers Stock Falls After FDA Warns on Super Bowl Campaign - ca.finance.yahoo.com
Hims and Hers stock faces pressure as BofA reiterates Underperform rating - Investing.com
Musk buys Tesla, China vs. US chips, Hims: Trending Tickers - Yahoo Finance
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know - Yahoo Finance
7,534 Shares in Hims & Hers Health, Inc. $HIMS Bought by City Center Advisors LLC - MarketBeat
Intech Investment Management LLC Boosts Stake in Hims & Hers Health, Inc. $HIMS - MarketBeat
2 Healthcare Stocks with Solid Fundamentals and 1 We Turn Down - FinancialContent
Hims & Hers Health's (HIMS) "Buy" Rating Reiterated at Canaccord Genuity Group - MarketBeat
Arete Wealth Advisors LLC Acquires New Position in Hims & Hers Health, Inc. $HIMS - MarketBeat
Alliancebernstein L.P. Has $24 Million Stock Holdings in Hims & Hers Health, Inc. $HIMS - MarketBeat
Time to Bet on Hims & Hers Health (HIMS)? Analysts Point to Several Growth Catalysts - TipRanks
Healthcare Stocks To Watch NowSeptember 12th - MarketBeat
Hims & Hers Super Bowl commercial faces FDA scrutiny amid crackdown on misleading ads - Seeking Alpha
Can Hims & Hers Health (HIMS) Redefine Its Growth Story With a New Focus on Hormone Health? - Yahoo Finance
US FDA chief says Super Bowl ad by Hims & Hers ‘breached’ drug promotion rules - 104.1 WIKY
Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks - Benzinga
US FDA chief says Hims & Hers Super Bowl ad violated drug promotion rules - Reuters
Trio In The Hot Medical Sector Is Led By This Retail Health Products Leader. Check Out IBD 50, Stock Spotlight Premium Lists. - Investor's Business Daily
US FDA chief says Super Bowl ad by Hims & Hers 'breached' drug promotion rules - Reuters
Hims & Hers Health (NYSE:HIMS) Trading 8.9% HigherWhat's Next? - MarketBeat
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why - Yahoo Finance
FDA Chief Says Hims’ Weight-Loss Drug Ad Breached Agency’s Rules - Bloomberg Law News
Hims & Hers Health Stock Surge: Analyzing the Growth - StocksToTrade
Healthcare Stocks To ConsiderSeptember 11th - MarketBeat
Hims & Hers Health (NYSE:HIMS) Shares Gap UpTime to Buy? - MarketBeat
Hims & Hers Leads 15 Growth Stocks Amid Medical Boom - Investor's Business Daily
Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock? - sharewise.com
Hims and Hers stock maintains Buy rating at BTIG despite GLP-1 slowdown - Investing.com
Scientech Research LLC Sells 8,163 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Investigation announced for Investors in shares of Hims & Hers Health, Inc. (NYSE: HIMS) over potential Wrongdoing - openPR.com
Notable Thursday Option Activity: HIMS, GRMN, EVC - Nasdaq
Hims & Hers Health, Inc. | 9/11/25 - ktnv.com
Hims expands into testosterone treatments - Sherwood News
Sustainable Weight Loss: Personalized Care with Hims & Hers - KNWA FOX24
Hims & Hers Looks Like Hyper Growth At A Reasonable Price (NYSE:HIMS) - Seeking Alpha
Ex-Stock Market Darling Hims Surges On A Long-Awaited Move - Investor's Business Daily
Best Medical Stocks Worth WatchingSeptember 9th - MarketBeat
Him and Her’s Health, Inc talks with Nicole DeCosta - KOIN.com
Hims & Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone - Stocktwits
Why Hims & Hers Health (HIMS) Stock Is Trading Up Today - Yahoo Finance
Hims & Hers Stock Jumps On Long-Awaited Foray Into Testosterone - Inkl
Hims & Hers Bets On Hormonal Health To Revive Investor ConfidenceHims & Hers Health (NYSE:HIMS) - Benzinga
Noteworthy ETF Outflows: VTWO, HIMS, FLR, IONQ - Nasdaq
Hims & Hers launches treatment plans for low testosterone - Reuters
Hims to Launch New Offerings for Men With Low Testosterone - Bloomberg.com
Hims Hers Health Inc Azioni (HIMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.77%
0.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):